Cargando…

Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/− oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Muhammad, Green, O’Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081018/
https://www.ncbi.nlm.nih.gov/pubmed/33948179
http://dx.doi.org/10.1093/omcr/omaa029
_version_ 1783685554663063552
author Ali, Muhammad
Green, O’Neil
author_facet Ali, Muhammad
Green, O’Neil
author_sort Ali, Muhammad
collection PubMed
description Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/− oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and others require fairly high daily oral corticosteroid dosing to achieve control, which in turn may induce the well-known effects of long term steroid use. The anti-interleukin drugs have been reported to help improve daily symptoms and reduce steroid requirements. Much of the literature highlights the benefit of omalizumab. We present a case of dupilumab as add-on therapy in a patient with ABPA, which allowed us to reduce daily steroid dosage.
format Online
Article
Text
id pubmed-8081018
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80810182021-05-03 Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis Ali, Muhammad Green, O’Neil Oxf Med Case Reports Case Report Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/− oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and others require fairly high daily oral corticosteroid dosing to achieve control, which in turn may induce the well-known effects of long term steroid use. The anti-interleukin drugs have been reported to help improve daily symptoms and reduce steroid requirements. Much of the literature highlights the benefit of omalizumab. We present a case of dupilumab as add-on therapy in a patient with ABPA, which allowed us to reduce daily steroid dosage. Oxford University Press 2021-04-28 /pmc/articles/PMC8081018/ /pubmed/33948179 http://dx.doi.org/10.1093/omcr/omaa029 Text en © The Author(s) 2021. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Ali, Muhammad
Green, O’Neil
Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title_full Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title_fullStr Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title_full_unstemmed Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title_short Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
title_sort dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081018/
https://www.ncbi.nlm.nih.gov/pubmed/33948179
http://dx.doi.org/10.1093/omcr/omaa029
work_keys_str_mv AT alimuhammad dupilumabanewcontestanttocorticosteroidinallergicbronchopulmonaryaspergillosis
AT greenoneil dupilumabanewcontestanttocorticosteroidinallergicbronchopulmonaryaspergillosis